Siren DIVCON股利领先ETF LEAD 深 沪
等待开盘 11-13 09:30:00 美东时间
85.9237
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 85.9237
- 总市值 62.13亿
- 52周最高 91.655
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 71.2208
- 委 比 0.00%
- 总股本 7230.30万
- 历史最高 91.655
- 量 比 0
- 振 幅 0.00%
- 历史最低 16.7469
- 每 手 1
- 风险率 4.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics reported promising Phase 1/2 data for vopimetostat plus daraxonrasib in pancreatic cancer, achieving an 82% ORR and 88% 9-month PFS. A registrational Phase 3 study is planned for 1H 2027. Vopimetostat data in NSCLC and TNG456 data in NSCLC, glioblastoma, and other cancers will be disclosed in January 2027. Cash position stands at $977.5 million as of September 30, 2026.
11-09 12:00
LEADING INDEPENDENT PROXY ADVISORY FIRM ISS RECOMMENDS RETAINING A MAJORITY OF ETHAN ALLEN DIRECTORS; DOES NOT ENDORSE DGB CONTROL
Ethan Allen reaffirms its five director nominees, disagreeing with ISS's recommendation to replace two of them. ISS questions DGB's proposal to replace the entire board, noting limited progress in their CEO search. Ethan Allen emphasizes the importance of continuity in leadership for a smooth CEO transition and urges shareholders to vote for their nominees on the BLUE proxy card.
10-27 13:09
EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe
Philips and the University Medical Center Groningen have launched the five-year EXIT-CVD project, co-funded by the European Union and industry partners, to transform cardiovascular disease detection, monitoring, and treatment. The project involves 42 partners across 17 countries, conducting 22 clinical studies with over 14,000 patients. It focuses on three key exit points: early detection, personalized interventions, and advanced therapies. The p...
10-15 08:00
Johnson & Johnson says long-term data boosts Icotyde for plaque psoriasis
New phase 3 data found that plaque psoriasis patients treated with Johnson & Johnson's (JNJ) Icotyde (icotrokinra) saw high levels of skin clearance after more than two years of treatment. In the pha...
10-09 23:54
Real-World Study Backs Long-Term Stability on BioArctic–Eisai Alzheimer’s Drug Leqembi
BioArctic AB Class B ( ($SE:BIOA.B) ) has shared an announcement. Real-world da...
07-14 23:32
